Jazz’s tremor drug candidate flops in Phase II study, misses primary endpoint
Jazz’s tremor drug candidate flops in Phase II study, misses primary endpoint
Jazz’s tremor drug candidate flops in Phase II study, misses primary endpoint
Published: Jun 21, 2024
By Tristan Manalac
BioSpace
Jazz Pharmaceuticals on Thursday reported that its investigational calcium channel modulator suvecaltamide missed its primary endpoint in a Phase IIb study, unable to significantly improve symptoms in patients with essential tremor.
The Dublin, Ireland-based biotech did not provide specific data in its announcement, only disclosing that the 30-mg dose of suvecaltamide “did not achieve statistical significance” versus placebo in terms of the modified composite outcome score in the Essential Tremor Rating Assessment Scale, a validated tool that quantifies tremor severity.
Suvecaltamide also did not hit its key secondary endpoint of Clinical Global Impression-Severity scale, which measures how severe patients’ symptoms are.
Jazz pointed to a greater-than-expected improvement in placebo patients, which exceeded the effects observed in a previous study of suvecaltamide.
Rob Iannone, executive vice president of global head of research and development at Jazz, in a statement said that the biotech is “disappointed” by these results. “We are evaluating the data to better understand the trial results … to determine next steps for the program.”
Despite falling short of statistical significance, Jazz touted the “numeric improvements” in tremor and overall symptom severity in patients treated with suvecaltamide.
The biotech also highlighted a strong safety and tolerability profile for suvecaltamide. The Phase IIb study found no new signals of concern, with the most common treatment-emergent adverse events being dizziness, headache, paresthesia, diarrhea and insomnia. Most side effects were mild to moderate in severity.
There was one instance of a serious adverse event, which the trial investigators deemed related to the study treatment.
Designed to be orally available, suvecaltamide is a selective and state-dependent small-molecule modulator of T-type calcium channels—which play a role in the brain’s control of muscle movement—and reduce their activity. This mechanism of action could help minimize uncontrolled movements in several neurological conditions.
Jazz is also assessing suvecaltamide in Parkinson’s disease, for which it is running a Phase II trial. The biotech enrolled the first patient in this trial in the fourth quarter of 2022.
Jazz’s neuroscience franchise has run into a rough patch in recent months. In December 2023, its post-traumatic stress disorder candidate JZP150 missed its primary endpoint in a Phase II study, failing to significantly improve symptoms versus placebo.
Tristan Manalac is an independent science writer based in Metro Manila, Philippines. Reach out to him on LinkedIn or email him at [email protected] or [email protected].
Source: BioSpace
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds: